ASSESSMENT OF EFFECTIVENESS OF SODIUM-GLUCOSE TRANSPORT PROTEIN-2 INHIBITORS IN TYPE-2 DIABETIC PATIENTS IN A TERTIARY CARE HOSPITAL – A LONGITUDINAL PROSPECTIVE STUDY

VEERENDRA KUMAR; STV RAGHAVAMMA

doi:10.22159/ajpcr.2025v18i9.55148

Authors

VEERENDRA KUMAR Department of Pharmacy Practice, Chalapathi Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India. https://orcid.org/0000-0001-5619-5028
STV RAGHAVAMMA Department of Pharmaceutics, Chalapathi Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India. https://orcid.org/0000-0002-9457-7331

DOI:

https://doi.org/10.22159/ajpcr.2025v18i9.55148

Keywords:

Sodium-glucose transport protein-2 inhibitors, Efficacy, Uncontrolled diabetes, Glycated hemoglobin

Abstract

Objectives: The main aim of the study was to assess the effectiveness of the sodium-glucose transport protein-2 inhibitors (SGLT-2i) in type 2 diabetic patients.

Methods: This was a prospective and longitudinal study conducted in a tertiary care center. During the study period, the data were collected from 200 diabetic patients, out of which 80 patients were followed up. Data collection form and informed consent were obtained from each patient.

Results: Out of 200 patients, 84 (42%) were female while 114 (58%) being male aged between 50 and 70 years had a higher prevalence of type 2 diabetes mellitus. Dapagliflozin was administered to 54 (67.5%) of the 80 patients, while empagliflozin was administered to 26 (32.5%). A total of 32 patients receiving dapagliflozin had baseline glycated hemoglobin (HbA1c) values of 7.6–9.0%, followed by >9% (n=16) and 6.5–7.5% (n=6), respectively. Sixteen patients receiving empagliflozin had baseline HbA1c values of 7.6–9.0%, followed by >9 (n=8) and 6.5–7.5% (n=2). After the start of the medicine, an average of gradual reduction of HbA1c was found to be 1.47%, while the study focused on the same.

Conclusion: SGLT-2i showed its action in lowering the blood glucose in patients who were adherent to the treatment regimen along with diet and exercise.

Downloads

Download data is not yet available.

References

1. Jiang J, Dutta S, Schneider S, Burley SK. Summer. 2016. Available from: https://pdb101.rcsb.org/global-health/diabetes-mellitus/about/ what-is-diabetes2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62-9. doi: 10.2337/dc10-S062, PMID 20042775

3. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013 Dec;15(12):1154-60. doi: 10.1111/dom.12185, PMID 23906374

4. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012 Jul;35(7):1473-8. doi: 10.2337/ dc11-1693, PMID 22446170, PMCID PMC3379599

5. Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: Effects on renal and intestinal glucose transport: From bench to bedside. Diabetes Care. 2015 Dec;38(12):2344-53. doi: 10.2337/dc15-0642, PMID 26604280

6. Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT- 2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/dmso.s34416, PMID 24348059, PMCID PMC3848644

7. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/ nejmoa1504720, PMID 26378978

8. Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S, Study 05 group. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: A 24- week Randomized, double-blind clinical trial. Diabetes Care. 2015 Mar;38(3):365-72. doi: 10.2337/dc14-0666, PMID 25592197

9. Neal B, Perkovic V, De Zeeuw D, Mahaffey KW, Fulcher G, Ways KM, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015 Mar;38(3):403-11. doi: 10.2337/dc14-1237, PMID 25468945

10. John M, Gopinath D, Jagesh R. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives. Indian J Endocrinol Metab. 2016;20(1):22-31. doi: 10.4103/2230-8210.172268, PMID 26904465

11. Kalra S. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: A systematic review. Cardiol Ther. 2016;5(2):161-8. doi: 10.1007/s40119-016-0069-z, PMID 27539303

12. Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932-8. doi: 10.4103/ijo.ijo_1627_21, PMID 34708726

13. Aloke C, Egwu CO, Aja PM, Obasi NA, Chukwu J, Akumadu BO, et al. Current advances in the management of diabetes mellitus. Biomedicines. 2022 Sep 29;10(10):2436. doi: 10.3390/biomedicines10102436, PMID 36289697, PMCID PMC9599361

14. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73-9. doi: 10.1097/ med.0000000000000311, PMID 27898586

15. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015 Jan;75(1):33-59. doi: 10.1007/s40265- 014-0337-y, PMID 25488697

16. Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015 Mar;38(3):376-83. doi: 10.2337/dc14-1142, PMID 25352655

17. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights. 2016;11:95-104. doi: 10.4137/bmi.s38440, PMID 27398023

18. Use of glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva: World Health Organization; 2011. PMID 26158184

19. Fong A, Serra AE, Gabby L, Wing DA, Berkowitz KM. Use of hemoglobin A1c as an early predictor of gestational diabetes mellitus. Am J Obstet Gynecol. 2014 Dec;211(6):641.e1-7. doi: 10.1016/j. ajog.2014.06.016, PMID 24912095

20. Luo B, Xu W, Luo F, Zhang S, Li X. Association between elevated glycosylated hemoglobin levels and hypertension among US adults: NHANES 2011-2018. BMC Cardiovasc Disord. 2025;25:58. doi: 10.1186/s12872-025-04503-3

21. Agrawal M, Tarun K, Mujumdar S, Neelesh A. A pharmacoeconomic evaluation of cost variation among various brands of anti-diabetic drugs currently available in India. Asian J Pharm Clin Res. 2023;16(4):203-6. doi: 10.22159/ajpcr.2023v16i4.49231

22. Bashier A, Khalifa AA, Rashid F, Abdelgadir EI, Al Qaysi AA, Ali R, et al. Efficacy and safety of SGLT2 inhibitors in reducing glycated hemoglobin and weight in Emirati patients with type 2 diabetes. J Clin Med Res. 2017 Jun;9(6):499-507. doi: 10.14740/jocmr2976w, PMID 28496550, PMCID PMC5412523

23. Rao PS, Batool S, Maniyar SA, Tunnisa F, Ali Sohail M, Ali MM, et al. A community-based survey to assess the prevalence and etiological factors for type II diabetes mellitus in the two regional states of southern India-A pilot study. Int J Pharm Pharm Sci. 2024;16(3):31-8. doi: 10.22159/ijpps.2024v16i3.50297